Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — 2021 BIO CEO & Investor Digital Conference
26 slides from Dyadic International's conference presentation, Feb 18, 2021
Slide 1: 2021 BIO CEO & Investor Digital Conference
DYADIC 2021 BIO CEO & Investor Digital Conference Dyadic Thermophilic Filamentous Fungus (C1-cells) Recombinant Glycoprotein Antigen Vaccines, Antibodies & Other Therapeutic Protein Product Production Platform February 15,2021
Slide 2: Safe Harbor Regarding Forward-looking Statements
Safe Harbor Regarding Forward-looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, i
Slide 3: Dyadic At A Glance
Dyadic At A Glance Solid Financial Position with Compelling Wholly Owned Products and Partnerships Market Capitalization Cash & Investment-grade securities, Applying Dyadie's proprietary & patented C1-cell including accrued interest ‘chromosomal gene expression and recombinant protein production pla
Slide 4: C1 is ideally suited to help meet the global demand for multivalent vaccines
C1 is ideally suited to help meet the global demand for multivalent vaccines & multi antibody cocktails E Building a more efficient biomanufacturing platform to serve a global population more affordably Sys AS Cova acca Esl Groorame Grodin Opportunistic participation in product development of ogame
Slide 5: Investment Highlights
Investment Highlights Solid Financial Position with $30.5 million in cash and investment securities, no debt! Top Tier Global Partners and Wholly Owned Programs Broadly applicable to subunit vaccines, therapeutics, enzymesand other peptide, le Platfon Vereatte Pletiorm protein and glycoprotein based
Slide 6: Addressable C1 Market Opportunities
Addressable C1 Market Opportunities Global and Growing End Market Opportunities Recombinant Subunit Vaccinesand en) f Vaccines and Therapeutics for environmental ‘TherapeuticProteins for Animal health (pandemics) and other biological threats, Global Market size - $11.3 Billion by 2025" } including C
Slide 7: 2021 Dyadic Focus
2021 Dyadic Focus BD Success & Momentum Towards first phase | clinical study with C1-RBD antigen against the Covi Leverage the success in developing C1 antigens against SARS-CoV-2 and animal viruses for ZAP| to expand the rVaccine pipeline for Human and Animal Health Continue to strengthen and expan
Slide 8: 2021 Dyadic Focus - Continue
2021 Dyadic Focus - Continue SARS-CoV-2 Animal Health Programs Human Biopharmaceutical Programs Continue to prepare for our potential Human Phase 1 Clinical Trial using a Dyadic owned C'-cell manufactured SARS- CoV-2 Receptor Binding Domain (RBD) recombinant antigen vaccine product candidate Demonst
Slide 9: IIBR Strategic Collaboration Helped To Position Dyadic to Enter Human Clinical Trials
IIBR Strategic Collaboration Helped To Position Dyadic to Enter Human Clinical Trials Israel Institute for Biological Research (IIBR) Demonstrated C1-cell produced SARS-CoV-2 Receptor Binding Domain (RBD) Can Be Manufactured In Large Quantities, At Low Cost, Which Neutralizes the COVID-19 Virus Isra
Slide 10: Phase 1 with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021
Phase | with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021 Initiate cGMP manufacturing, conducting toxicology, initiating and completion of an anticipated Human Phase 4 Clinical Trial Of a C1 produced SARS-CoV-2 vaccine candidate. Prove Safety & Efficacy In Humans DYADIC” Developed the C1-RBD p
Slide 11: SARS-CoV-2 (Infectious Disease) Strategy For Global Populations
SARS-CoV-2 (Infectious Disease) Strategy For Global Populations TetraValent Recombinant Variant Antigen SARS-CoV-2 Vaccine Product Candidates Four critical Variant RBDs in preparation for C1-cell manufacturing of Dyadic-4TVA™ Antigen-encoded SARS-CoV-2 vaccine candidate arate Sending samples ealztio
Slide 12: ZAPI success leads to fully funded collaborations
ZAPI success leads to fully funded collaborations with several leading global animal & human health companies and governmental agencies EU Government ZAPI Collaboration Further Positions C1 Products For Potential Human Cli al Trials Zoonoses Anticipation Preparedness Initiative (ZAPI) + 2015-2021 €2
Slide 13: Platform R&D / Technology Transfer
Platform R&D / Technology Transfer Glyco-Protein Engineering of C1-cells: Advance Dyadic’s Nivolumab (Opdivo®) Biosimilar MADAS Proof of Concept for Production of mAbs, Protease Engineering (l.e., protease deletions) of C1-cells ‘SARS-CoV-2, Influenza other Infectious Disease Pathogens. Growth Facto
Slide 14: Human Biopharmaceutical Programs - Nivolumab (Opdivo) Biosimilar mAb Candidate
Human Biopharmaceutical Programs - Nivolumab (Opdivo®) a Biosimilar mAb Candidate Anti-Cancer mAb, Manufacturing Nivolumab (Opdivo®) manufactured by Brisiol Myers ‘Squibb, is an ‘mmunotherapeutc biologic Mab drug for human metastatic cancers, including melanoma lung & other cancers j.e., Anti-PD-1 I
Slide 15: C1-Cell High Value Recombinant Protein Production Platforms Competitive Advantages
C1-CELL HIGH VALUE RECOMBINANT PROTEIN PRODUCTION PLATFORMS COMPETITIVE ADVANTAGES
Slide 16: Filamentous Fungus C1-Cell High Level Protein Production
Filamentous Fungus C1-Cell High Level Protein Production High Purities & Exceptional Yields/Stabilities with Scalable Benefits for Protein Based Product Manufacturing 1-cells are thermophilic filamentous fungi with highly desirable growth and manufacturingproperties joped to produce large quantities
Slide 17: C1-Cell Recombinant Protein Products With Competitive Advantages
C1-Cell Recombinant Protein Products With Competitive Advantages Robust Recombinant Protein Production Platform Offers Competitive Advantages Over Existing Techs ° 6 Purities fe} ts] Productivity Robustness High retention of target secreted protein(s) or other C1-cell bloproduct(s) through downstrea
Slide 18: C1-Cell Recombinant Protein Production Broadly Applied For Biologics
C1-Cell Recombinant Protein Production Broadly Applied For Biologics C1-Cells Enable Commercial Manufacture Of Rapid, Cost-Effective, High Value, Safe, Effective Protein Products High Yields and Purities Demonstrated for Therapeutic Monoclonal Antibodies (mAbs) and Vaccine Antigen GlycoProteins' Fe-
Slide 19: Returns on Investments from Focused Business Development
RETURNS ON INVESTMENTS FROM FOCUSED BUSINESS DEVELOPMENT
Slide 20: Business Development Strategy
Business Development Strategy External development programs help advance C1 recombinant protein platform and fund R&D initiatives Co-Development /Technology Licensing Allows Dyadic to developand advance C1 recombinant protein tech at low costto Company Big Pharmas Funded proof of concept collaborati
Slide 21: Investment Highlights
Investment Highlights Solid Financial Position with $30.5 mi n in cash and investment securities, no debt! Top Tier Global Partners and Wholly Owned Programs Versatile Platform Strong Competitive Advantage& IP Position Global Business Development Global Strategic Partnerships Experienced Leadership
Slide 22: Management & Directors With Track Record Of Success/Value Creation
Management & Directors With Track Record Of Success/Value Creation Highly Energized Professional Management Team with Deep Industry Expertise & Products In Market Active Board with Decades of Relevant Experience in Biomanufacturing Ping Rawson Deloitte. ee DYADIC’ 20+ years of finance, accounting &
Slide 23: Global Need For Rapid, Safe, Scalable Vaccine Antigen & Antibody Manufacturing
Global Need For Rapid, Safe, Scalable Vaccine Antigen & Antibody Manufacturing SARS-CoV-2 pandemic highlights unmet needs for rapid MonoValent, DiValent, Trivalent or MultValent but also high scale-up, straight-forward tech transfer to rapidly and cost-effectively meet global needs for several bilio
Slide 24: C1-Cell Manufacture SARS-CoV-2 Global Recombinant Vaccine & Monoclonal Antibody Strategic Programs
C1-Cell Manufacture SARS-CoV-2 Global Recombinant Vaccine & Monoclonal Antibody Strategic Programs Nine development programs carried out globally; Additional Programs Under Discussion North America ‘South America 2
Slide 25: Dyadic International Summary & Vision
Dyadic International Summary & Vision + To accelerate the adoption & use of C1-Cells to speed the development, lower the cost, improve the performance while providing the necessary quantities of vaccines & drugs to a global population more affordably. + Strategy to deliver thermophilic filamentous f
Slide 26: Contact
Contact: memalfarb@dyadic.com North America South America Altica (including Middle East) www.dyadic.com
Dyadic International — 2021 BIO CEO & Investor Digital Conference on 6ix